Project Grant R01AG093992
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research at Virginia Commonwealth University (VCU) to investigate the effect of the trans-synaptic spread of pathogenic tau protein in the hippocampus and its impact on vulnerable neuron subtypes in Alzheimer's disease (AD). The $408,638 award, effective from August 1, 2024 to July 31, 2026, will involve the use of adeno-associated viral vector transfection, immunofluorescence, and...
- This $130,302 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research at New York University School of Medicine to investigate the selective vulnerability of basal forebrain cholinergic neurons (BFCNs) to tau pathology in Alzheimer's disease (AD). The key products and services to be delivered include: Investigating the biochemical underpinnings and functional alterations of BFCNs with pathological tau accumulation using human induced...
- The Project Grant award titled "ENHANCER-AAVS TO MONITOR AND RESTORE CELL-TYPE SELECTIVE INHIBITORY DEFICITS AND CIRCUIT DYSFUNCTION IN HUMANIZED ALZHEIMER'S DISEASE MODELS" was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The $1,459,072.00 award, granted to the J. David Gladstone Institutes, aims to monitor and manipulate inhibitory interneuron cell populations in mouse models to assess their contribution to...
- This federal Project Grant award of $716,579, awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to investigate the role of microglia, the immune cells of the brain, in the progression of Alzheimer's disease (AD). Specifically, the research aims to genetically dissect the relationships between different activated states of microglia and their involvement in complement-mediated synapse loss, which is a key neurobiological driver of cognitive decline in...
- This $426,674 federal grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), supports research to investigate the implications of long-range mossy cell signaling and connectivity in Alzheimer's disease (AD). The project aims to identify ways to remediate the cognitive and emotional impairments associated with AD, with a focus on understanding the role of the dentate gyrus (DG) region of the hippocampus and the activity of glutamatergic mossy...
- This Project Grant award of $1,083,046.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to generate novel adeno-associated viruses (AAVs) that can selectively target oligodendrocyte precursor cells (OPCs) in the central nervous system. The two-phase project will then leverage these OPC-selective AAV vectors to investigate the hypothesis that reactive changes in OPCs surrounding amyloid plaques can reduce plaque burden in Alzheimer's disease model mice. This...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $804,450.00 to support research conducted by the J. David Gladstone Institutes in San Francisco, CA aimed at "Targeting NELL2 and GABAergic Dysfunction to Mitigate ApoE4-Driven Pathogenesis in Alzheimer's Disease." The research will investigate how the Alzheimer's disease risk factor ApoE4 interacts with sex and aging to contribute to neuronal network hyperactivity and cognitive...
- This federal Project Grant award, titled "Selective Vulnerability of Fronto-Insular Network in Aging and Alzheimer's Disease", is funded by the National Institute on Aging (CFDA 93.866 - Aging Research) for a total of $656,829. The award will be carried out by the University of Rochester from January 1, 2026 to December 31, 2030. The primary objectives of this research project are to investigate the selective vulnerability of the fronto-insular network in the context of aging and...
- This Project Grant award of $445,130 from the National Institute on Aging (CFDA 93.866 Aging Research program) aims to elucidate the mechanisms by which MS4A genes regulate neurodegeneration in Alzheimer's disease and related disorders. The research is being conducted by the University of Massachusetts Medical School from January 1, 2026 to December 31, 2030. The project seeks to build on prior findings that genetic deletion of the MS4A6C gene significantly improves cognitive, behavioral, and...
- This $792,498 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research by the Trustees of Indiana University, doing business as Indiana University Indianapolis, to investigate the role of P2X7 receptor signaling in neuroinflammation and neurodegeneration in Alzheimer's disease and related dementias (ADRD). The key objectives are to: 1) characterize mouse models of ADRD to assess neuroinflammation, synaptic density, and neuronal health...
This federal Project Grant award of $552,883 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to study how the interaction between soluble oligomeric amyloid-beta 42 (oAβ42) and α7β2-containing nicotinic acetylcholine receptors (α7β2-nAChRs) contributes to the selective degeneration of basal forebrain cholinergic neurons in Alzheimer's disease. The research will use whole-cell patch-clamp recordings to determine how α7β2-nAChRs modulate the activity of specific potassium channel subtypes in distinct forebrain cholinergic regions, and how these alterations drive cholinergic neuron dysfunction under the influence of oAβ42. This project, awarded to Virginia Commonwealth University, will run from January 1, 2026 to November 30, 2030 and contribute to the National Institute on Aging's mission of supporting biomedical and behavioral research to better understand aging processes and age-related diseases like Alzheimer's.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $552.9k | 12/26/25 |